Anzeige
Mehr »
Samstag, 06.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40W1C | ISIN: US2936025046 | Ticker-Symbol:
NASDAQ
05.09.25 | 19:36
2,120 US-Dollar
-0,93 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENSYSCE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ENSYSCE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur ENSYSCE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoEnsysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium171~ Experts Spotlight TAAP and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")...
► Artikel lesen
19.08.Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025203~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~~ Ensysce Biopharma Leader to Deliver...
► Artikel lesen
13.08.Ensysce Biosciences GAAP EPS of -$0.79, revenue of $1.37M2
13.08.Ensysce Biosciences, Inc. - 10-Q, Quarterly Report2
13.08.Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates475Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Protection...
► Artikel lesen
13.08.Ensysce Biosciences, Inc. - 8-K, Current Report4
31.07.Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback202~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Benefits...
► Artikel lesen
ENSYSCE BIOSCIENCES Aktie jetzt für 0€ handeln
16.07.Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse430~ FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")...
► Artikel lesen
24.06.Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2208~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Development Program ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce...
► Artikel lesen
11.06.Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025231~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical...
► Artikel lesen
05.06.Ensysce Biosciences ernennt Baker Tilly zum neuen Wirtschaftsprüfer1
05.06.Ensysce Biosciences, Inc. - 8-K, Current Report3
04.06.Ensysce Flat on Receiving Grant-
04.06.Ensysce Biosciences sichert sich zusätzliche 5,3 Millionen US-Dollar NIDA-Förderung2
04.06.Ensysce Biosciences secures additional $5.3M NIDA grant3
04.06.Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection211~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences...
► Artikel lesen
13.05.Ensysce Biosciences Reports First Quarter 2025 Financial Results334Receives U.S. Patent for Groundbreaking Treatment for Opioid Use DisorderClinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025...
► Artikel lesen
13.05.Ensysce Biosciences, Inc. - 10-Q, Quarterly Report2
12.05.Ensysce Biosciences Bolsters Management Team with Regulatory Expert252~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical...
► Artikel lesen
02.05.Ensysce Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1